SCHEMBL6796040

SCHEMBL6796040

CC(=O)Nc1ccc(C2=N/C(=C/c3ccccc3)C(=O)O2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 3/20 0.60
CSNK2B P67870 3/20 0.60
CSNK2A1 P68400 3/20 0.60
NOTUM Q6P988 1/20 0.58
DAPK3 O43293 2/20 0.53
F2 P00734 1/20 0.53
F10 P00742 1/20 0.53
PLG P00747 1/20 0.53
PLAU P00749 1/20 0.53
PLAT P00750 1/20 0.53
KLKB1 P03952 1/20 0.53
PLCG2 P16885 1/20 0.52
ALDH1A1 P00352 3/20 0.52
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
KMT2A Q03164 3/20 0.51
MEN1 O00255 2/20 0.51
MAPK1 P28482 1/20 0.50
GAA P10253 1/20 0.47
POLB P06746 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6796043 1.00 CSNK2A2 (0.60) CSNK2A2CSNK2BCSNK2A1NOTUMDAPK3
SCHEMBL22501219 0.84 CSNK2A2 (0.53) CSNK2A2CSNK2BCSNK2A1NOTUMF2
SCHEMBL22501218 0.84 CSNK2A2 (0.53) CSNK2A2CSNK2BCSNK2A1NOTUMF2
SCHEMBL22505164 0.84 SMN1; SMN2 (0.49) CSNK2A2CSNK2BCSNK2A1ALDH1A1MAPT
SCHEMBL24241499 0.84 SMN1; SMN2 (0.49) CSNK2A2CSNK2BCSNK2A1ALDH1A1MAPT
SCHEMBL22500814 0.84 CSNK2A2 (0.47) CSNK2A2CSNK2BCSNK2A1NOTUMDAPK3
SCHEMBL29518145 0.81 CSNK2A2 (0.46) CSNK2A2CSNK2BCSNK2A1NOTUMDAPK3
SCHEMBL22505139 0.81 KDM4E (0.47) CSNK2A2CSNK2BCSNK2A1NOTUMF2
SCHEMBL22505788 0.81 CSNK2A2 (0.46) CSNK2A2CSNK2BCSNK2A1NOTUMDAPK3
SCHEMBL29518009 0.81 KDM4E (0.47) CSNK2A2CSNK2BCSNK2A1NOTUMF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis WARNER-LAMBERT COMPANY LLC 2004-09-16 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040180943-A1 Oxazolone analogs as amyloid aggregation inhibitors and for the treatment of alzheimer's disease and disorders related to amyloidosis APP, PSEN1, PSEN2 CSNK2A2 1982/4885CSNK2B 1874/4885CSNK2A1 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.